Huw Morris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2006607/publications.pdf

Version: 2024-02-01

246 papers	24,672 citations	14655 66 h-index	8866 145 g-index
266 all docs	266 docs citations	266 times ranked	27265 citing authors

#	Article	IF	Citations
1	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
2	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	21.4	1,685
3	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
4	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
5	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
6	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	10.2	1,039
7	Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry,the, 2020, 7, 875-882.	7.4	1,005
8	Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology, 2000, 54, 697-697.	1.1	401
9	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology, 2001, 56, 1702-1706.	1.1	392
10	Excessive burden of lysosomal storage disorder gene variants in Parkinsonâ€™s disease. Brain, 2017, 140, 3191-3203.	7.6	323
11	Visual dysfunction in Parkinsonâ€™s disease. Brain, 2016, 139, 2827-2843.	7.6	320
12	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
13	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and Î±â€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
14	Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases. JAMA Neurology, 2017, 74, 780.	9.0	245
15	Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiology of Aging, 2014, 35, 1779.e5-1779.e13.	3.1	234
16	The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain, 2001, 124, 1438-1449.	7.6	226
17	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Human Molecular Genetics, 2011, 20, 345-353.	2.9	202
18	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198

#	Article	IF	Citations
19	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	1.9	196
20	Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. Acta Neuropathologica, 2017, 133, 337-352.	7.7	193
21	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurology, The, 2015, 14, 1002-1009.	10.2	179
22	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2012, 21, 4996-5009.	2.9	176
23	Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain, 2016, 139, 1904-1918.	7.6	170
24	Parkinsonâ€™s disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2014, 137, 2480-2492.	7.6	169
25	The effect of onset age on the clinical features of Parkinsonâ€™s disease. European Journal of Neurology, 2009, 16, 450-456.	3.3	151
26	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149
27	Systematic Review and UKâ€Based Study of PARK2 (parkin), PINK1, PARK7 (DJâ€1) and LRRK2 in earlyâ€onset Parkinson's disease. Movement Disorders, 2012, 27, 1522-1529.	3.9	141
28	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
29	Progress towards therapies for disease modification in Parkinson's disease. Lancet Neurology, The, 2021, 20, 559-572.	10.2	136
30	Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology, 2013, 80, 2042-2048.	1.1	129
31	Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. Movement Disorders, 2016, 31, 1518-1526.	3.9	128
32	Clinical genetics of familial progressive supranuclear palsy. Brain, 1999, 122, 1233-1245.	7.6	124
33	The motor phenotype of Parkinson's disease in relation to age at onset. Movement Disorders, 2011, 26, 457-463.	3.9	122
34	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	2.9	122
35	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
36	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Human Molecular Genetics, 2015, 24, 5260-5269.	2.9	116

#	Article	IF	Citations
37	Developing and validating Parkinsonâ€™s disease subtypes and their motor and cognitive progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1279-1287.	1.9	116
38	<scp>LRRK</scp> 2 activation controls the repair of damaged endomembranes in macrophages. EMBO Journal, 2020, 39, e104494.	7.8	116
39	The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging, 2012, 33, 209.e3-209.e8.	3.1	115
40	Polygenic risk of <scp>P</scp>arkinson disease is correlated with disease age at onset. Annals of Neurology, 2015, 77, 582-591.	5.3	115
41	The Genetic and Pathological Classification of Familial Frontotemporal Dementia. Archives of Neurology, 2001, 58, 1813.	4.5	114
42	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nature Medicine, 2019, 25, 152-164.	30.7	111
43	A Missense Mutation in KCTD17 Causes Autosomal Dominant Myoclonus-Dystonia. American Journal of Human Genetics, 2015, 96, 938-947.	6.2	109
44	NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiology of Aging, 2017, 57, 247.e9-247.e13.	3.1	108
45	Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain, 2016, 139, 3237-3252.	7.6	107
46	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 152-164.	1.9	107
47	The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 665-667.	1.9	103
48	Features of GBA-associated Parkinsonâ€™s disease at presentation in the UK Tracking Parkinsonâ€™s study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 702-709.	1.9	103
49	Genomeâ€Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Movement Disorders, 2021, 36, 424-433.	3.9	101
50	Discovery and functional prioritization of Parkinsonâ€™s disease candidate genes from large-scale whole exome sequencing. Genome Biology, 2017, 18, 22.	8.8	96
51	Mitochondria function associated genes contribute to Parkinsonâ€™s Disease risk and later age at onset. Npj Parkinson's Disease, 2019, 5, 8.	5.3	95
52	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology, 2021, 78, 464.	9.0	95
53	Increased fractional anisotropy in the motor tracts of Parkinson's disease suggests compensatory neuroplasticity or selective neurodegeneration. European Radiology, 2016, 26, 3327-3335.	4.5	94
54	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	9.0	94

#	Article	IF	Citations
55	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
56	SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain, 2013, 136, 294-303.	7.6	91
57	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Molecular Neurodegeneration, 2015, 10, 41.	10.8	90
58	Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 805-807.	1.9	89
59	Tau exon 10 +16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. Neurology, 2003, 61, 102-104.	1.1	86
60	Clinical features of frontotemporal dementia due to the intronic tau 10 ⁺¹⁶ mutation. Neurology, 2002, 58, 1161-1168.	1.1	85
61	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinsonâ€™s disease heritability. Npj Parkinson's Disease, 2019, 5, 6.	5.3	83
62	Multiple system atrophy/progressive supranuclear palsy: Î±-Synuclein, synphilin, tau, and APOE. Neurology, 2000, 55, 1918-1920.	1.1	82
63	Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain, 2002, 125, 969-975.	7.6	80
64	Parkinson's Disease â€“ the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. Journal of Parkinson's Disease, 2013, 3, 1-11.	2.8	79
65	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
66	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. Parkinsonism and Related Disorders, 2018, 56, 27-32.	2.2	77
67	Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosomeÂ9p. Journal of Neurology, 2011, 258, 647-655.	3.6	76
68	Client and therapist views on exercise programmes for early-mid stage Parkinson's disease and Huntington's disease. Disability and Rehabilitation, 2010, 32, 917-928.	1.8	75
69	Genetic risk and age in Parkinson's disease: Continuum not stratum. Movement Disorders, 2015, 30, 850-854.	3.9	71
70	Sub-populations of smaller diameter trigeminal primary afferent neurons defined by expression of calcitonin gene-related peptide and the cell surface oligosaccharide recognized by monoclonal antibody LA4.. Journal of Neurocytology, 1991, 20, 716-731.	1.5	69
71	Genetics of Parkinson's disease. Annals of Medicine, 2005, 37, 86-96.	3.8	67
72	Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA Neurology, 2018, 75, 1416.	9.0	66

#	Article	IF	Citations
73	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
74	Upbeat nystagmus: clinicoanatomical correlation. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 380-381.	1.9	65
75	Recent advances in Parkinsonâ€™s disease genetics. Journal of Neurology, 2014, 261, 259-266.	3.6	65
76	Early myoclonic status and outcome after cardiorespiratory arrest. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 267-268.	1.9	64
77	Tracking Parkinsonâ€™s: Study Design and Baseline Patient Data. Journal of Parkinson's Disease, 2015, 5, 947-959.	2.8	64
78	Quality of life in youngâ€•compared with lateâ€•onset Parkinson's disease. Movement Disorders, 2011, 26, 2011-2018.	3.9	63
79	Defining neurodegeneration on <scp>G</scp>uam by targeted genomic sequencing. Annals of Neurology, 2015, 77, 458-468.	5.3	63
80	Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Current Treatment Options in Neurology, 2016, 18, 42.	1.8	63
81	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine, 2021, 27, 1451-1457.	30.7	63
82	Genetic analysis of Mendelian mutations in a large UK population-based Parkinsonâ€™s disease study. Brain, 2019, 142, 2828-2844.	7.6	62
83	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
84	Parkinson's disease: chameleons and mimics. Practical Neurology, 2015, 15, 14-25.	1.1	61
85	SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype. Journal of Neurology, 2014, 261, 2296-2304.	3.6	59
86	Genetic comorbidities in Parkinson's disease. Human Molecular Genetics, 2014, 23, 831-841.	2.9	57
87	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56
88	Clinical and genetic characteristics of nonâ€Asian dentatorubralâ€pallidoluysian atrophy: A systematic review. Movement Disorders, 2009, 24, 1636-1640.	3.9	54
89	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3140-3151.	3.1	53
90	Analysis of Genome-Wide Association Studies of Alzheimer Disease and of Parkinson Disease to Determine If These 2 Diseases Share a Common Genetic Risk. JAMA Neurology, 2013, 70, 1268-76.	9.0	51

#	Article	IF	Citations
91	Analysis of tau haplotypes in Pickâ€™s disease. Neurology, 2002, 59, 443-445.	1.1	50
92	Recent Advances in the Genetics of the ALS-FTLD Complex. Current Neurology and Neuroscience Reports, 2012, 12, 243-250.	4.2	50
93	CHCHD2 and Parkinson's disease. Lancet Neurology, The, 2015, 14, 678-679.	10.2	50
94	The Parkinson's Disease Mendelian Randomization Research Portal. Movement Disorders, 2019, 34, 1864-1872.	3.9	50
95	Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders. Brain, 2020, 143, 2771-2787.	7.6	50
96	Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. Neuroscience Letters, 2001, 311, 145-148.	2.1	49
97	Neuropathologic variation in frontotemporal dementia due to the intronic tau 10 ⁺¹⁶ mutation. Neurology, 2002, 58, 1169-1175.	1.1	49
98	Variation in tau isoform expression in different brain regions and disease states. Neurobiology of Aging, 2013, 34, 1922.e7-1922.e12.	3.1	49
99	Benign hereditary chorea related to <scp>NKX</scp>2.1: expansion of the genotypic and phenotypic spectrum. Developmental Medicine and Child Neurology, 2014, 56, 642-648.	2.1	49
100	Functional Magnetic Resonance Imaging Neurofeedback-guided Motor Imagery Training and Motor Training for Parkinsonâ€™s Disease: Randomized Trial. Frontiers in Behavioral Neuroscience, 2016, 10, 111.	2.0	49
101	Sequence of clinical and neurodegeneration events in Parkinsonâ€™s disease progression. Brain, 2021, 144, 975-988.	7.6	49
102	Additional rare variant analysis in Parkinsonâ€™s disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance. Human Molecular Genetics, 2016, 25, ddw348.	2.9	48
103	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
104	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 33, 96-101.	2.2	46
105	Can neuroimaging predict dementia in Parkinsonâ€™s disease?. Brain, 2018, 141, 2545-2560.	7.6	46
106	C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism. Movement Disorders, 2012, 27, 1072-1074.	3.9	45
107	Genome-Wide Analysis of the Parkinsonism-Dementia Complex of Guam. Archives of Neurology, 2004, 61, 1889-97.	4.5	44
108	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS ONE, 2012, 7, e43099.	2.5	44

#	Article	IF	Citations
109	Multi-modality machine learning predicting Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, 35.	5.3	44
110	Mutation in thetau exon 10 splice site region in familial frontotemporal dementia. Annals of Neurology, 1999, 45, 270-271.	5.3	43
111	Aripiprazole associated with severe exacerbation of Parkinson's disease. Movement Disorders, 2006, 21, 1538-1539.	3.9	43
112	Hyposmia in progressive supranuclear palsy. Movement Disorders, 2010, 25, 570-577.	3.9	43
113	Psychiatric disorders, myoclonus dystonia and <scp>SGCE</scp> : an international study. Annals of Clinical and Translational Neurology, 2016, 3, 4-11.	3.7	43
114	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.8	42
115	Perry syndrome due to the DCTN1 G71R mutation: A distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure. Movement Disorders, 2010, 25, 767-770.	3.9	41
116	Psychiatric disorders, myoclonus dystonia, and the epsilonâ€sarcoglycan gene: A systematic review. Movement Disorders, 2011, 26, 1939-1942.	3.9	41
117	Neurofibrillary tangle parkinsonian disorders?tau pathology andtau genetics. Movement Disorders, 1999, 14, 731-736.	3.9	40
118	Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins. Neurology, 2010, 75, 367-372.	1.1	40
119	Neurodegenerative diseases of Guam: Analysis of TAU. Neurology, 1999, 53, 411-411.	1.1	40
120	A clinical and pathological study of motor neurone disease on Guam. Brain, 2001, 124, 2215-2222.	7.6	39
121	Late onset startle induced tics. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 782-784.	1.9	37
122	Familial early onset frontotemporal dementia caused by a novel S356T MAPT mutation, initially diagnosed as schizophrenia. Clinical Neurology and Neurosurgery, 2010, 112, 917-920.	1.4	37
123	Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	5.3	37
124	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
125	Assessing the relationship between monoallelic PRKN mutations and Parkinsonâ€™s risk. Human Molecular Genetics, 2021, 30, 78-86.	2.9	36
126	Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgraduate Medical Journal, 1999, 75, 579-584.	1.8	35

#	Article	IF	Citations
127	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. Movement Disorders Clinical Practice, 2017, 4, 509-516.	1.5	35
128	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	2.2	34
129	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinsonâ€™s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The â€˜Exenatide-PD3â€™ study. BMJ Open, 2021, 11, e047993.	1.9	32
130	Chaperone-mediated autophagy as a therapeutic target for Parkinson disease. Expert Opinion on Therapeutic Targets, 2018, 22, 823-832.	3.4	31
131	The Impact of Type 2 Diabetes in Parkinson's Disease. Movement Disorders, 2022, 37, 1612-1623.	3.9	30
132	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 768-773.	1.9	29
133	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
134	Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997â€“2000. Neurology, 2002, 59, 1121-1121.	1.1	28
135	Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. Neurobiology of Aging, 2014, 35, 1512.e5-1512.e10.	3.1	28
136	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. Neuroscience Letters, 1999, 260, 193-195.	2.1	27
137	Strong association of the Saitohin gene Q7 variant with progressive supranuclear palsy. Neurology, 2003, 61, 407-409.	1.1	27
138	Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Neuroscience Letters, 2001, 312, 118-120.	2.1	26
139	Clinical skills evaluation of trainees in a neurology department. Clinical Medicine, 2007, 7, 365-369.	1.9	26
140	Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 883-888.	1.9	26
141	The Catsâ€andâ€Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease. Movement Disorders, 2017, 32, 1789-1790.	3.9	26
142	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
143	The genetic aetiology of late-onset chronic progressive cerebellar ataxia. Journal of Neurology, 2009, 256, 343-348.	3.6	25
144	Precompetitive Data Sharing as a Catalyst toÂAddress Unmet Needs in Parkinsonâ€™s Disease 1. Journal of Parkinson's Disease, 2015, 5, 581-594.	2.8	25

#	Article	IF	Citations
145	Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuoâ€perceptual deficits. Movement Disorders, 2018, 33, 544-553.	3.9	25
146	Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes. Neurology: Genetics, 2021, 7, e557.	1.9	25
147	Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation. American Journal of Medical Genetics Part A, 2004, 125B, 79-82.	2.4	24
148	Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1183-1190.	1.9	24
149	Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiology of Aging, 2012, 33, 838.e7-838.e11.	3.1	23
150	Dentatorubral pallidoluysian atrophy in South Wales. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 804-807.	1.9	22
151	Spontaneous ARIA (Amyloid-Related Imaging Abnormalities) and Cerebral Amyloid Angiopathy Related Inflammation in Presenilin 1-Associated Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1069-1074.	2.6	22
152	Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury. Brain Communications, 2020, 2, fcaa137.	3.3	22
153	Primary antiphospholipid syndrome presenting as a corticobasal degeneration syndrome. Movement Disorders, 1999, 14, 530-532.	3.9	21
154	The effect of age and the H1c MAPT haplotype on MAPT expression in human brain. Neurobiology of Aging, 2009, 30, 1652-1656.	3.1	21
155	Variation in Recent Onset Parkinsonâ€™s Disease: Implications for Prodromal Detection. Journal of Parkinson's Disease, 2016, 6, 289-300.	2.8	21
156	Olfaction inParkinsingle and compound heterozygotes in a cohort of young onset Parkinson's disease patients. Acta Neurologica Scandinavica, 2016, 134, 271-276.	2.1	21
157	Cooperative Genome-Wide Analysis Shows Increased Homozygosity in Early Onset Parkinson's Disease. PLoS ONE, 2012, 7, e28787.	2.5	21
158	Sign language tics in a prelingually deaf man. Movement Disorders, 2000, 15, 318-320.	3.9	19
159	Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease. Neurobiology of Aging, 2016, 48, 222.e1-222.e7.	3.1	19
160	Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate. Neurocase, 2018, 24, 204-212.	0.6	19
161	A novel TBK1 mutation in a family with diverse frontotemporal dementia spectrum disorders. Journal of Physical Education and Sports Management, 2019, 5, a003913.	1.2	19
162	No pathogenic mutations in the synphilin-1 gene in Parkinson's disease. Neuroscience Letters, 2001, 307, 125-127.	2.1	18

#	Article	IF	Citations
163	Exome sequencing expands the mutational spectrum of SPG8 in a family with spasticity responsive to l-DOPA treatment. Journal of Neurology, 2013, 260, 2414-2416.	3.6	18
164	Is the MC1R variant p.R160W associated with Parkinson's?. Annals of Neurology, 2016, 79, 159-161.	5.3	18
165	Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 388-390.	1.9	17
166	Neural correlates of early cognitive dysfunction in Parkinson's disease. Annals of Clinical and Translational Neurology, 2019, 6, 902-912.	3.7	17
167	The genetic and clinicoâ€pathological profile of earlyâ€onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	3.9	16
168	REM sleep behaviour disorder: an early window for prevention in neurodegeneration?. Brain, 2019, 142, 498-501.	7.6	16
169	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinsonâ€™s disease. Neurobiology of Aging, 2021, 97, 148.e17-148.e24.	3.1	16
170	Automated Brainstem Segmentation Detects Differential Involvement in Atypical Parkinsonian Syndromes. Journal of Movement Disorders, 2020, 13, 39-46.	1.3	16
171	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. Parkinsonism and Related Disorders, 2017, 40, 40-46.	2.2	15
172	Establishing the role of rare coding variants in known Parkinson's disease risk loci. Neurobiology of Aging, 2017, 59, 220.e11-220.e18.	3.1	15
173	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	10.2	15
174	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15
175	Case control analysis of repeat expansion size in ataxia. Neuroscience Letters, 2007, 429, 28-32.	2.1	14
176	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. Parkinsonism and Related Disorders, 2019, 65, 55-61.	2.2	14
177	ATP10B and the risk for Parkinsonâ€™s disease. Acta Neuropathologica, 2020, 140, 401-402.	7.7	14
178	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	3.9	13
179	The frequency of spinocerebellar ataxia type 23 in a UK population. Journal of Neurology, 2013, 260, 856-859.	3.6	12
180	A data-driven model of brain volume changes in progressive supranuclear palsy. Brain Communications, 2022, 4, .	3.3	12

#	Article	IF	Citations
181	Update on fluid biomarkers for concussion. Concussion, 2016, 1, CNC12.	1.0	11
182	Sensitivity and Specificity of the ECAS in Parkinsonâ€™s Disease and Progressive Supranuclear Palsy. Parkinson's Disease, 2018, 2018, 1-8.	1.1	11
183	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	2.2	11
184	Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. Movement Disorders Clinical Practice, 2020, 7, 394-398.	1.5	11
185	MAPT p.V363I mutation. Neurology: Genetics, 2019, 5, e347.	1.9	10
186	Parkinsonism following electrical injury to the hand. Movement Disorders, 1998, 13, 600-602.	3.9	9
187	Analysis of copy number variation using quantitative interspecies competitive PCR. Nucleic Acids Research, 2008, 36, e112-e112.	14.5	9
188	Parkinâ€related disease clinically diagnosed as a pallidoâ€pyramidal syndrome. Movement Disorders, 2009, 24, 138-140.	3.9	9
189	Distal hereditary motor neuropathy with vocal cord paresis: from difficulty in choral singing to a molecular genetic diagnosis. Practical Neurology, 2016, 16, 247-251.	1.1	9
190	BRain health and healthy AgeINg in retired rugby union players, the BRAIN Study: study protocol for an observational study in the UK. BMJ Open, 2017, 7, e017990.	1.9	9
191	Identification of UBAP1 mutations in juvenile hereditary spastic paraplegia in the 100,000 Genomes Project. European Journal of Human Genetics, 2020, 28, 1763-1768.	2.8	9
192	Combining biomarkers for prognostic modelling of Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 707-715.	1.9	9
193	Investigation of Somatic Mutations in Human Brains Targeting Genes Associated With Parkinson's Disease. Frontiers in Neurology, 2020, 11, 570424.	2.4	8
194	The PINK1â€”Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells. PLoS ONE, 2021, 16, e0259903.	2.5	8
195	Genomeâ€Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor. Movement Disorders, 2020, 35, 705-707.	3.9	7
196	Decision-making, attitudes, and understanding among patients and relatives invited to undergo genome sequencing in the 100,000 Genomes Project: A multisite survey study. Genetics in Medicine, 2022, 24, 61-74.	2.4	7
197	Use of corticosteroids to suppress drug toxicity in complicated tuberculosis. Journal of Infection, 1999, 39, 237-240.	3.3	6
198	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. Movement Disorders, 2001, 16, 382-395.	3.9	6

#	Article	IF	Citations
199	Young onset limb spasticity with PSP-like brain and spinal cord NFT-tau pathology. Neurology, 2005, 64, 731-733.	1.1	6
200	A novel presenilin 1 mutation, I202F occurring at a previously predicted pathogenic site causing autosomal dominant Alzheimer's disease. Neurobiology of Aging, 2011, 32, 556.e1-556.e2.	3.1	6
201	Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. Frontiers in Neurology, 2021, 12, 679927.	2.4	6
202	Elevated 4Râ€tau in astrocytes from asymptomatic carriers of the MAPT 10+16 intronic mutation. Journal of Cellular and Molecular Medicine, 2022, 26, 1327-1331.	3.6	6
203	Clinical grand round: A rapidly progressive pyramidal and extrapyramidal syndrome with a supranuclear gaze palsy. Movement Disorders, 2005, 20, 826-831.	3.9	5
204	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2014, 23, 562-562.	2.9	5
205	Clinical Features and Differential Diagnosis of Parkinsonâ€™s Disease. , 2017, , 103-115.		5
206	Longitudinal risk factors for developing depressive symptoms in Parkinson's disease. Journal of the Neurological Sciences, 2021, 429, 117615.	0.6	5
207	Atypical parkinsonism in the French West Indies. Lancet, The, 1999, 354, 1474.	13.7	4
208	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
209	Pathogenetic insights into young-onset Parkinson disease. Nature Reviews Neurology, 2020, 16, 245-246.	10.1	4
210	Comparison between four published definitions of hyposmia in Parkinson's disease. Brain and Behavior, 2021, 11, e2258.	2.2	4
211	Diagnosing Premotor Multiple System Atrophy. Neurology, 2022, 99, .	1.1	4
212	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2013, 22, 1696-1696.	2.9	3
213	Early Onset Parkinsonâ€™s Disease in a family of Moroccan origin caused by a p.A217D mutation in PINK1: a case report. BMC Neurology, 2017, 17, 153.	1.8	3
214	The long-term outcome of impulsive compulsive behaviours in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1288-1289.	1.9	3
215	Revisiting the assessment of tremor: clinical review. British Journal of General Practice, 2020, 70, 611-614.	1.4	3
216	Whole-genome sequencing. Practical Neurology, 2021, 21, 322-327.	1.1	3

#	Article	IF	Citations
217	Reply. Movement Disorders, 2000, 15, 587-588.	3.9	2
218	Autosomal dominant Parkinsonâ€™s disease and the route to new therapies. Expert Review of Neurotherapeutics, 2007, 7, 649-656.	2.8	2
219	SGCZ mutations are unlikely to be associated with myoclonus dystonia. Neuroscience, 2014, 272, 88-91.	2.3	2
220	Late-onset cytoplasmic body myopathy resembling myotonic dystrophy. , 1999, 22, 781-782.		1
221	POMD03 Association of head injury with Parkinson's disease risk by age at onset. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e58-e58.	1.9	1
222	[P1â€“258]: THE PROSPECT STUDY: DEVELOPMENT OF A UKâ€BASED LONGITUDINAL OBSERVATIONAL STUDY OF PSP, CBD, MSA AND ATYPICAL PARKINSONISM SYNDROMES. Alzheimer's and Dementia, 2017, 13, P348.	0.8	1
223	Association, expression, pathobiology. Neurology, 2008, 71, 11-12.	1.1	0
224	POMD10 Do psychiatric disorders form part of the myoclonus-dystonia syndrome phenotype? A systematic review of published literature. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e59-e60.	1.9	0
225	PATH42 Lineage, clinical, genetic, structural and cellular characterisation of a novel epilepsy mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e19-e19.	1.9	0
226	1624â€…Myoclonus dystonia: a clinical and genetic description: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.146-e1.	1.9	0
227	BNSU SURVEILLANCE PROJECT: MYOCLONUS DYSTONIA SYNDROME. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.184-e2.	1.9	0
228	FAMILY HISTORY IN YOUNG ONSET PARKINSON'S DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.69-e2.	1.9	0
229	DISTAL SPINAL MUSCULAR ATROPHY WITH VOCAL PARESIS: FROM THE WELSH CHOIR TO GENES. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.117-e2.	1.9	0
230	TRACKING PARKINSON'S (THE PROBAND STUDY)â€“INTERIM REPORT FROM THE FIRST 1000 CASES. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.70-e2.	1.9	0
231	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2013, 22, 2973-2973.	2.9	0
232	EFFECTS OF VASCULAR COMORBIDITY IN PARKINSON'S DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.13-e1.	1.9	0
233	DEEP PHENOTYPING OF THE G2019S LRRK2 MUTATION IN PARKINSON'S DISEASE: UCL COHORT. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.16-e1.	1.9	0
234	CHANGE IN VISUAL FUNCTION IN PARKINSON'S DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.18-e1.	1.9	0

#	Article	IF	Citations
235	PARKINSON'S FAMILIES PROJECT: RECRUITMENT OF FAMILIAL PD PATIENTS VIA THE BNSU. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.20-e1.	1.9	0
236	CORTICOBASAL SYNDROME AND CORTICOBASAL DEGENERATION. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.9-e1.	1.9	0
237	John Stuart Morris. BMJ: British Medical Journal, 2017, 357, j1748.	2.3	0
238	Reply: MRI findings of visual system alterations in Parkinsonâ€™s disease. Brain, 2017, 140, e70-e70.	7.6	0
239	[O4â€“02â€“01]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON's AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1228.	0.8	0
240	1115â€…Chronic traumatic encephalopathy in retired footballers with dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A1.1-A1.	1.9	0
241	Small spiral, big mass. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1189-1190.	1.9	0
242	Making neurogenetics a global endeavour. Brain, 2020, 143, 1970-1973.	7.6	0
243	Investigating the contribution of an intronic variation at the trim11 locus to pathological and clinical heterogeneity in progressive supranuclear palsy. Alzheimer's and Dementia, 2020, 16, e042936.	0.8	0
244	The parkinsonism dementia complex of Guam and flying foxes. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2002, , 12-12.	0.1	0
245	236â€… Systemic mitochondrial dysfunction in monogenic Parkinsonâ€™s disease as a potential biomarker for stratification. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A81.3-A81.	1.9	0
246	228â€… Testing shortened versions of smell tests to screen for hyposmia in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A79.2-A79.	1.9	0